Drug intelligence / Profile preview

ChAd3-hliNSmut

Development stage
Phase 1
Lead developer
ReiThera
Modality
Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intramuscular
01

Overview

ChAd3-hliNSmut is a prophylactic vaccine candidate developed for the prevention of hepatitis C virus (HCV) infection. It utilizes a chimpanzee adenovirus serotype 3 (ChAd3) vector encoding a mutated form of the HCV nonstructural proteins, with an invariant chain adjuvant to enhance immunogenicity. The vaccine is designed to stimulate robust CD4+ and CD8+ T cell responses against HCV antigens, aiming to provide protective immunity by boosting cellular immune responses. The primary indication for ChAd3-hliNSmut is chronic hepatitis C infection, and it has been studied in combination with MVA-hliNSmut as part of prime-boost vaccination regimens in early-phase clinical trials. The vaccine was initially developed at Oxford University and ReiThera Srl, with further development by GlaxoSmithKline[1][6][7][8].

02

Targets

γδ TCR (T-cell receptor)

Beyond the preview

Go deeper on ChAd3-hliNSmut.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ChAd3-hliNSmut.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call